Phase i and pharmacokinetic study of dacomitinib (PF-00299804), an oral irreversible, small molecule inhibitor of human epidermal growth factor receptor-1,-2, and-4 tyrosine kinases, in Japanese patients with advanced solid tumors

Investigational New Drugs

Volumn 30, Issue 6, 2012, Pages 2352-2363

  Takahashi, Toshiaki ^a   Boku, Narikazu ^a   Murakami, Haruyasu ^a   Naito, Tateaki ^a   Tsuya, Asuka ^a   Nakamura, Yukiko ^a   Ono, Akira ^a   Machida, Nozomu ^a   Yamazaki, Kentaro ^a   Watanabe, Junichiro ^a   Ruiz Garcia, Ana ^b   Imai, Keiji ^b   Ohki, Emiko ^b   Yamamoto, Nobuyuki ^a  

^a SHIZUOKA CANCER CENTER   (Japan)

^b PFIZER INC   (United States)

Author keywords

Dacomitinib; Epidermal growth factor receptor; Japanese patients; PF 00299804; Phase I; Tyrosine kinase inhibitor

Indexed keywords

DACOMITINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 1; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 4; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ANTINEOPLASTIC ACTIVITY; APPETITE; ARTICLE; BILIRUBIN BLOOD LEVEL; BODY WEIGHT; CHEILITIS; CLINICAL ARTICLE; CONJUNCTIVITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; DRY SKIN; EDEMA; FATIGUE; FEMALE; FOLLOW UP; HAND FOOT SYNDROME; HEMATURIA; HUMAN; HYPERTRICHOSIS; JAPANESE; LEUKOPENIA; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; PARONYCHIA; PHARMACOKINETICS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEINURIA; QT PROLONGATION; SIDE EFFECT; SINGLE DRUG DOSE; SKIN FISSURE; SOLID TUMOR; STOMATITIS;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; CARCINOMA, NON-SMALL-CELL LUNG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS; QUINAZOLINONES; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TUMOR BURDEN;

EID: 84875487595     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-011-9789-z     Document Type: Article

References (27)

1. Yarden Y, Sliwkowski MX (2001) Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2:127-137
2. Salomon DS, Brandt R, Ciardiello F, Normanno N (1995) Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 19:183-232
3. Woodburn JR (1999) The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol Ther 82:241-250
4. Mendelsohn J, Baselga J (2003) Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 21:2787-2799
5. Engelman JA, Zejnullahu K, Gale CM et al (2007) PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. Cancer Res 67:11924-11932
6. Gonzales AJ, Hook KE, Althaus IWet al (2008) Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor. Mol Cancer Ther 7:1880-1889
7. Shigematsu H, Takahashi T, Nomura M et al (2005) Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 97:339-346
8. Kobayashi S, Boggon TJ, Dayaram T et al (2005) EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 352:786-792
9. Pao W, Miller VA, Politi KA et al (2005) Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2:e73
10. Balak MN, Gong Y, Riely GJ et al (2006) Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Clin Cancer Res 12:6494-6501
11. Janne PA, Boss DS, Camidge DR et al (2011) Phase I dose-escalation study of the pan-HER inhibitor, PF299804, in patients with advanced malignant solid tumors. Clin Cancer Res 17:1131-1139
12. Janne P, Reckamp K, Koczywas M, et al. (2009) Efficacy and safety of PF-00299804 (PF299) in patients (pt) with advanced NSCLC after failure of at least one prior chemotherapy regimen and prior treatment with erlotinib (E): A two-arm, phase II trial. J Clin Oncol 27(suppl.) (abstr. 8063)
13. Ramalingam SS, Boyer MJ, Park K, et al. (2010) Randomized phase 2 study of PF299804, an irreversible human epidermal growth factor receptor (EGFR) inhibitor, versus (v) erlotinib (E) in patients (pts) with advanced non-small cell lung cancer (NSCLC) after chemotherapy (CT) failure: quantitative and qualitative benefits. Ann Oncol 21(suppl. 8) (abstr. 365PD)
14. Siu LL, Hotte SJ, Laurie SA, et al. (2011) Phase II trial of the irreversible oral pan-human EGF receptor (HER) inhibitor PF-00299804 (PF) as first-line treatment in recurrent and/or metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN). J Clin Oncol 29(suppl.) (abstr. 5561)
15. Schellens JH, Britten CD, Camidge DR, et al. (2007) First-inhuman study of the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of PF-00299804, a small molecule irreversible panHER inhibitor in patients with advanced cancer. J Clin Oncol 25(suppl.) (abstr. 3599)
16. Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216
17. FDA Advisory Committee Briefing Document: Pharmaceutical Science and Clinical Pharmacology Advisory Committee, March 18-19, 2008 (http://www.fda.gov/ ohrms/dockets/ac/08/briefing/2008-4351b1-00-index.htm)
18. Park K, Heo DS, Cho BC, et al. (2010) PF299804 in Asian patients with non-small cell lung cancer refractory to chemotherapy and erlotinib or gefitinib-a phase 1/2 study. J Clin Oncol 28(suppl.) (abstr. 7599)
19. Hartmann JT, Haap M, Kopp HG, Lipp HP (2009) Tyrosine kinase inhibitors-a review on pharmacology, metabolism and side effects. Curr Drug Metab 10:470-481
20. Li T, Perez-Soler R (2009) Skin toxicities associated with epidermal growth factor receptor inhibitors. Target Oncol 4:107-119
21. Ouwerkerk J, Boers-Doets C (2010) Best practices in the management of toxicities related to anti-EGFR agents for metastatic colo-rectal cancer. Eur J Oncol Nurs 14:337-349
22. Heo DS, Kim JH, Cho BC, et al. (2009) First report of PF-00299804 in Asian patients: a Korean phase I/II study in KRAS wild-type, stage IIIb/IV non-small cell lung cancer, refractory to chemotherapy and erlotinib or gefitinib. Oral presentation at the 13th World Conference on Lung Cancer, San Francisco, CA, USA, 2009
23. Engelman JA, Zejnullahu K, Mitsudomi T et al (2007) MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316:1039-1043
24. Innovation/stagnation: challenge and opportunity on the critical path to new medical products. March 2004 (http://www.fda.gov/ScienceResearch/ SpecialTopics/CriticalPathInitiative/Critical PathOpportunitiesReports/ ucm077262.htm)
25. End-of-phase 2a meetings. FDA guidance for Industry. September 2009 (http://www.fda.gov/downloads/Drugs/Guidance ComplianceRegulatoryInformation/ Guidances/ucm079690.pdf) (accessed April 16, 2010)
26. Wang Y, Sung C, Dartois C et al (2009) Elucidation of relationship between tumor size and survival in non-small-cell lung cancer patients can aid early decision making in clinical drug development. Clin Pharmacol Therapeutics 86:167-174
27. Campbell A, Reckamp KL, Camidge DR, et al. (2010) PF-00299804 (PF299) patient (pt)-reported outcomes (PROs) and efficacy in adenocarcinoma (adeno) and nonadeno non-small cell lung cancer (NSCLC): A phase (P) II trial in advanced NSCLC after failure of chemotherapy (CT) and erlotinib (E). J Clin Oncol 28(suppl.) (abstr. 7596)